Johnson & Johnson (JNJ)vsScienture Holdings, Inc. (SCNX)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
SCNX
Scienture Holdings, Inc.
$0.39
+5.08%
HEALTHCARE · Cap: $15.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 22326073% more annual revenue ($96.36B vs $431,610). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SCNX
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+15.5%
Fair Value
$0.53
Current Price
$0.39
$0.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 1870.0%
Revenue surging 810.0% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -55.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : SCNX
The strongest argument for SCNX centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 810.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SCNX is a hypergrowth play — different risk/reward profiles.
SCNX is growing revenue faster at 810.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 43/100), backed by strong 21.8% margins. SCNX offers better value entry with a 15.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is a biotechnology company dedicated to advancing therapeutic solutions for neurological disorders through its innovative drug development pipeline. Leveraging cutting-edge technology and a highly proficient research team, Scienture aims to address significant unmet medical needs while enhancing patient outcomes. The company's unwavering commitment to scientific excellence, regulatory adherence, and strategic partnerships not only fuels its growth prospects but also underscores its potential to deliver impactful contributions to global healthcare advancements. As the healthcare sector continues to expand, SCNX is well-positioned to capitalize on emerging opportunities in the neurological treatment landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?